Placebo News and Research

RSS

Vanda reports clinical data of tasimelteon Phase III studies for treatment of Non-24-Hour Disorder

Vanda Pharmaceuticals Inc. presented additional entrainment and patient-level clinical data at SLEEP 2013, the 27th Annual Meeting of Associated Professional Sleep Societies in Baltimore, from its SET (Safety and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal study of the Efficacy and Safety of Tasimelteon to treat Non-24-Hour Disorder) Phase III studies of tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder (Non-24) in totally blind individuals.

6 Jun 2013

Allergic rhinitis treatments: an interview with Dr Dermot Ryan, GP and allergy expert

Allergic rhinitis is most commonly recognized as hay fever in the United Kingdom and it is due to the impact of an allergen, in the case of hay fever a pollen, setting off an inflammatory response in the lungs, causing typical symptoms...

5 Jun 2013

Michigan Tech study: Fish oil supplements may protect the heart in stressful situations

Fish oil supplements may protect the heart in stressful situations, according to a recent study. Jason Carter, a researcher at Michigan Technological University, conducted the study with 67 healthy volunteer test participants in their 20s.

5 Jun 2013

PROLOR Biotech announces initiation of hGH-CTP Phase III trial in growth hormone deficient adults

PROLOR Biotech, Inc., a company developing next-generation biobetter therapeutic proteins, today announced the initiation of a pivotal Phase III clinical trial of hGH-CTP, the company's proprietary version of human growth hormone, in growth hormone deficient adults.

4 Jun 2013

Naurex initiates Phase I trial of NRX-1074 in normal volunteers

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has begun patient dosing in a Phase I trial of its novel, orally active agent NRX-1074.

4 Jun 2013

Tel Aviv University researchers find protein modification may help control Alzheimer's and epilepsy

In the brain, cell-to-cell communication is dependent on neurotransmitters, chemicals that aid the transfer of information between neurons. Several proteins have the ability to modify the production of these chemicals by either increasing or decreasing their amount, or promoting or preventing their secretion.

4 Jun 2013

Research: Bevacizumab fails to increase overall survival for glioblastoma patients

The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center.

3 Jun 2013

Study investigates gene expression signature to predict response to bevacizumab

A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin-), according to new research from The University of Texas MD Anderson Cancer Center.

3 Jun 2013

MRIgFU ablation therapy reduces pain in 67% of patients with bone tumors

Patients with cancer that has spread to their bones are often treated with radiation therapy to reduce pain. But if that treatment doesn't work, or can't be used again, a second, effective option now exists.

3 Jun 2013

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology's annual meeting.

3 Jun 2013

Genetically engineered immune cells appear to promote healing in mice infected with MS-like disease

Genetically engineered immune cells seem to promote healing in mice infected with a neurological disease similar to multiple sclerosis (MS), cleaning up lesions and allowing the mice to regain use of their legs and tails.

1 Jun 2013

Glioblastoma patients treated with bevacizumab have deterioration in neurocognitive function

Many glioblastoma patients treated with bevacizumab (Avastin-) have significant deterioration in neurocognitive function, symptoms and quality of life. Not only that, the changes often predict treatment outcomes, according to new research from The University of Texas MD Anderson Cancer Center.

1 Jun 2013

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection.

31 May 2013

Ragweed allergy sublingual immunotherapy: an interview with Dr. Peter Creticos, Johns Hopkins University School of Medicine

Ragweed is a dominant seasonal allergen in North America (~26% of US and North American population is allergic to this noxious weed which pollinates from early August to early October).

31 May 2013

Comprehensive analyses of the benefits and risks of NSAIDs

Charles H. Hennekens, MD, DrPH, the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University has published in the current issue of The Lancet the most comprehensive analyses of the benefits and risks of non-steroidal anti-inflammatory drugs, which include cyclo-oxygenase-2 inhibitors (coxibs).

31 May 2013

Research explores connections between the brain, immune system and psychological functions

It's true that the brain governs the body, but the body also governs the brain, for example when the immune defense system makes us rest when we're sick. This is shown in research that the world's leading researchers and Nobel laureates will be presenting at an international conference in the research field of psychoneuroimmunology in Stockholm in June.

30 May 2013

Doctors perform investigational procedure on six patients using ADRCs to treat heart failure

Doctors at the Texas Heart Institute at St. Luke's Episcopal Hospital announced that they have performed an investigational procedure on six patients in a new FDA-approved clinical trial to evaluate therapy that uses regenerative cells derived from a patient's own adipose (body fat) tissue to treat a severe form of heart failure.

30 May 2013

Targacept initiates TC-5214 Phase 2b clinical study in patients with OAB

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced the initiation of a Phase 2b clinical study of TC-5214 as a treatment for overactive bladder.

29 May 2013

Pacira Pharmaceuticals reports results of EXPAREL Phase 2/3 clinical trial for TKA

Pacira Pharmaceuticals, Inc. today announced findings from the completed first part of its Phase 2/3 clinical trial assessing the use and administration of EXPAREL (bupivacaine liposome injectable suspension) as a single-dose injection femoral nerve block for total knee arthroplasty surgery.

29 May 2013

Unique omega-3 supplement improves lung function, reduces airway inflammation in asthmatics

An Indiana University study has found that a unique omega-3 supplement derived from the New Zealand green-lipped mussel significantly improved lung function and reduced airway inflammation in asthmatics who experience exercise-induced bronchoconstriction, also called exercise-induced asthma.

29 May 2013

Placebo News and Research

Vanda reports clinical data of tasimelteon Phase III studies for treatment of Non-24-Hour Disorder

Allergic rhinitis treatments: an interview with Dr Dermot Ryan, GP and allergy expert

Michigan Tech study: Fish oil supplements may protect the heart in stressful situations

PROLOR Biotech announces initiation of hGH-CTP Phase III trial in growth hormone deficient adults

Naurex initiates Phase I trial of NRX-1074 in normal volunteers

Tel Aviv University researchers find protein modification may help control Alzheimer's and epilepsy

Research: Bevacizumab fails to increase overall survival for glioblastoma patients

Study investigates gene expression signature to predict response to bevacizumab

MRIgFU ablation therapy reduces pain in 67% of patients with bone tumors

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

Genetically engineered immune cells appear to promote healing in mice infected with MS-like disease

Glioblastoma patients treated with bevacizumab have deterioration in neurocognitive function

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

Ragweed allergy sublingual immunotherapy: an interview with Dr. Peter Creticos, Johns Hopkins University School of Medicine

Comprehensive analyses of the benefits and risks of NSAIDs

Research explores connections between the brain, immune system and psychological functions

Doctors perform investigational procedure on six patients using ADRCs to treat heart failure

Targacept initiates TC-5214 Phase 2b clinical study in patients with OAB

Pacira Pharmaceuticals reports results of EXPAREL Phase 2/3 clinical trial for TKA

Unique omega-3 supplement improves lung function, reduces airway inflammation in asthmatics

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News